Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: Long-term analysis of intervention in RS with vaccine for patients with previous HBV infection

Transplant Infectious Disease

Volumn 16, Issue 5, 2014, Pages 797-801

  Takahata, M ^a   Hashino, S ^b   Onozawa, M ^a   Shigematsu, A ^a   Sugita, J ^a   Fujimoto, K ^a   Endo, T ^a   Kondo, T ^a   Tanaka, J ^c   Imamura, M ^d   Teshima, T ^a  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^d SAPPORO HOKUYU HOSPITAL   (Japan)

Author keywords

HBV; Reverse seroconversion; Stem cell transplantation; Vaccine

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; REVERSE SEROCONVERSION; SEROCONVERSION; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT; BLOOD; DRUG EFFECTS; HEPATITIS B VIRUS; IMMUNOLOGY; MIDDLE AGED; POSTOPERATIVE CARE; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TIME; VIRUS ACTIVATION;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TIME FACTORS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84907934932     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12283     Document Type: Article

References (22)

1. Goyama S, Kanda Y, Nannya Y, et al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 2002; 43: 2159-2163.
2. Degos F, Lugassy C, Degott C, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. Gastroenterology 1988; 94: 151-156.
3. Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989; 4: 207-208.
4. Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627-629.
5. Onozawa M, Hashino S, Izumiyama K, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-619.
6. Onozawa M, Hashino S, Darmanin S, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008; 14: 1226-1230.
7. Park S, Kim K, Kim DH, et al. Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus. Biol Blood Marrow Transplant 2011; 17: 1630-1637.
8. Viganò M, Vener C, Lampertico P, et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 125-131.
9. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 2007; 14: 478-483.
10. Dhédin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 66: 616-619.
11. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1049-1059.
12. Giaccone L, Festuccia M, Marengo A, et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 809-817.
13. Ilan Y, Nagler A, Adler R, et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 1993; 18: 246-252.
14. Wimperis JZ, Brenner MK, Prentice HG, et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986; 1: 339-343.
15. Kaloyannidis P, Batsis I, Yannaki E, et al. Allografted recipients immunized against hepatitis B virus are at high risk of gradual surface antibody (HBsAb) disappearance post transplant, regardless of adoptive immunity transfer. Biol Blood Marrow Transplant 2007; 13: 1049-1056.
16. Ljungman P, Engelhard D, de la Camara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005; 35: 737-746.
17. Locasciulli A, Testa M, Valsecchi MG, et al. Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: a 10-year prospective study. Blood 1997; 90: 3799-3805.
18. Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 2006; 108: 2470-2475.
19. del Pozo Balado Mdel M, Leal M, Méndez Lagares G, et al. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis 2010; 202 (3): 362-369.
20. McNeela EA, Mills KH. Manipulating the immune system: humoral versus cell-mediated immunity. Adv Drug Deliv Rev 2001; 51: 43-54.
21. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-1742.
22. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24: 572-577.